Abstract
Background:Targeting specific tissues remains a major challenge to the promise of gene therapy. For example, several strategies have failed to target adeno-associated virus 2 (AAV2) vectors, to bone. We have evaluated in vitro and in vivo the affinity of an AAV2 vector to bone matrix, hydroxyapatite (HA) to treat Mucopolysacccharidosis IVA.Methods:To increase vector affinity to HA, an aspartic acid octapeptide (D8) was inserted immediately after the N-terminal region of VP2 capsid protein. The modified vector had physical titers and transduction efficiencies comparable to the unmodified vector.Results:The bone-targeting vector had significantly higher HA affinity and vector genome copies in bone than the unmodified vector. The modified vector was also released from HA, and its enzyme activity in bone, three months post-infusion, was 4.7-fold higher than the unmodified vector.Conclusion:Inserting a bone-targeting peptide into the vector capsid increases gene delivery and expression in bone without decreasing enzyme expression. This approach could be a novel strategy to treat systemic bone diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
